Stock Market Reviews

Read and share opinions on BIIB (Biogen Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers
  Dec 22, 2025
• Biogen (BIIB) Stock Trades Up, Here Is Why
  Dec 19, 2025
• Biogen (BIIB): Reassessing Valuation After a Recent 3-Month Share Price Rebound
  Dec 18, 2025
• HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress
  Dec 17, 2025

BIIB News

• UnitedHealth Works Toward Recovery and 4 More Healthcare Themes to Watch in 2026
  Much in the new year depends on the fundamentals, which remain as complicated as ever. Watch these stocks.
  Dec 29, 2025
• 5 Healthcare Themes for Investors to Watch in 2026
  Much in the new year depends on the fundamentals, which remain as complicated as ever. Watch these stocks.
  Dec 28, 2025
• The Bull Case For Biogen (BIIB) Could Change Following New QALSODY ALS Data And Nasdaq-100 Exit - Learn Why
  In recent days, Biogen has reported long-term Phase 3 and extension data showing its ALS therapy QALSODY can slow SOD1-ALS progression and, in some cases, help patients regain lost function, while the company was also removed from the Nasdaq-100 index. At the same time, mixed analyst views now center on how QALSODY’s data, Biogen’s Alzheimer’s drug Leqembi, and its emerging multiple sclerosis pipeline might reshape the company’s future earnings mix as it adapts to index removal. We’ll now...
  Dec 23, 2025
• Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers
  As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) and its peers.
  Dec 22, 2025
• The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
  Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants regained previously lost function and strength, something not previously reported in the natural history of SOD1-ALSBiogen is committed to advancing additional ALS research, including the ongoing QALSODY ATLAS study in pre-symptomatic SOD1-ALS and a robust discovery pipeline in ALS CAMBRIDGE, Mass., Dec
  Dec 22, 2025
• 1 Nasdaq 100 Stock Worth Your Attention and 2 Facing Headwinds
  The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.
  Dec 19, 2025
• Biogen (BIIB) Stock Trades Up, Here Is Why
  Shares of biotech company Biogen (NASDAQ:BIIB) jumped 2.8% in the morning session after RBC Capital reiterated an "Outperform" rating and a $210 price target on the stock, naming it a top large-cap pick for 2026.
  Dec 19, 2025
• Biogen (BIIB): Reassessing Valuation After a Recent 3-Month Share Price Rebound
  Biogen (BIIB) has quietly outperformed the market over the past 3 months, with shares up about 20%. This performance has put the stock back on investor radars after a stretch of weaker multi year returns. See our latest analysis for Biogen. That 19.6% 3 month share price return stands out against a still modest 14.7% year to date share price gain and a disappointing 3 year total shareholder return of around negative 40%. This suggests sentiment has only recently started to warm up again. If...
  Dec 18, 2025
• HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress
  We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. On December 10, TheFly reported that HSBC downgraded BIIB from Hold to Reduce, and lowered its price target to $143, citing concerns that BIIB’s reliance on royalty streams and challenges in its core business could weigh on future earnings and […]
  Dec 17, 2025
• MicroStrategy Gets to Stay in the Nasdaq-100. Does It Deserve to Stay in Your Portfolio Too?
  MSTR was being eyed for possible Nasdaq-100 removal, but when the index reconstitutes next week, it will get to stay. Other companies, including Biogen and Lululemon, will be removed.
  Dec 17, 2025
• Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117%
  Biotech leader Stoke stock is running up toward a new buy point. The company's revenue surged 117% in Q3.
  Dec 16, 2025
• 3 Mid-Cap Stocks We Find Risky
  Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
  Dec 15, 2025
• 200% Surge? These 6 Stocks Just Crashed the Nasdaq 100 Party
  Seagate, Western Digital lead a stunning reshuffle as tech laggards like Lululemon and Trade Desk get the boot.
  Dec 15, 2025
• Lululemon Set to Exit Nasdaq 100 as Index Adds New Members
  Annual rebalancing brings shifts across major tech and growth names
  Dec 15, 2025
• MicroStrategy retains place in key index despite delisting threats
  Michael Saylor's Bitcoin (BTC) treasury company, Strategy (Nasdaq: MSTR), earlier known as MicroStrategy, has been successful in retaining its spot in the Nasdaq 100 (NDQ). A benchmark stock market index in the U.S., the Nasdaq 100 tracks hundred of the largest non-financial ...
  Dec 15, 2025
• Bitcoin hoarding company Strategy remains in Nasdaq 100
  Bitcoin hoarding giant Strategy clung to its place in the Nasdaq 100 on ​Friday, continuing its year-long stint in the benchmark ‌at a time where analysts have raised questions over its business ‌model. Some market watchers have suggested Strategy's pioneering business model of buying-and-holding bitcoin, which has spawned dozens of copycats, more closely resembles that of an investment fund. Nasdaq said Biogen, ‍CDW Corporation, Globalfoundries, Lululemon Athletica, On Semiconductor and Trade Desk were removed from the tech-heavy exchange's benchmark index.
  Dec 13, 2025
• Analysts flag risks for Strategy at Nasdaq 100 index reshuffle
  Bitcoin hoarding giant Strategy may be at risk of being removed from the Nasdaq 100 index at its annual reshuffle on Friday, amid questions over its business model that have weighed ​on its share price, some analysts flagged this week. After a sizzling rally that pushed its market capitalization to a peak of $128 billion earlier this ‌year, Strategy - which started out as software company MicroStrategy but pivoted to bitcoin investing in 2020 - was included last December under the index's technology sub-category. Strategy reported a net profit of $2.78 billion for the three months ended September 30, compared with a loss of $340.2 million a year earlier, mostly driven by an accounting change that allowed it to book gains on its bitcoin holdings.
  Dec 12, 2025
• Why Analysts See Biogen’s Story Shifting Toward Undervalued Growth Potential
  Biogen's fair value estimate has nudged higher to about $178.76 per share, even as its discount rate ticks up slightly to roughly 7.49 %, signaling a modestly higher perceived risk backdrop. The shift reflects a cautiously constructive Street narrative that balances near term execution risks with growing confidence in longer term drivers such as Leqembi, the core neurology franchise, and late stage pipeline assets. Stay tuned to learn how you can track these evolving assumptions and the...
  Dec 11, 2025
• Does Biogen’s Recent Share Price Rebound Reflect Its True Value in 2025?
  If you have been wondering whether Biogen's recent share price makes it a bargain or a value trap, you are not alone. This article is designed to help you cut through the noise and focus on what the numbers are really saying. The stock has climbed 13.6% over the last month and is up 18.4% year to date, even though it is still down sharply over 3 and 5 years. That hints at a possible shift in how the market is reassessing its long term prospects and risk profile. Recent headlines have...
  Dec 11, 2025
• 3 Healthcare Stocks We Think Twice About
  Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately - over the past six months, healthcare stocks have gained 13.5%, nearly mirrorring the S&P 500.
  Dec 11, 2025
• HSBC highlights one pharma stock to buy and one to sell for 2026
  Investing.com -- HSBC shifted its ratings across U.S. large-cap pharmaceuticals in a note on Wednesday, led by Rajesh Kumar, upgrading AbbVie to Buy while cutting Biogen to Reduce, as the bank refreshed its 2026 sector outlook.
  Dec 10, 2025
• Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls
  Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls
  Dec 10, 2025
• Great Point Partners Acquires a Majority Stake in Lenis Group, a Full-Service Specialty Pharmaceutical Commercialization and Distribution Partner
  GREENWICH, Conn. & LJUBLJANA, Slovenia, December 10, 2025--Great Point Partners ("GPP" or "the Firm"), a Greenwich-based private investment firm focused exclusively on the healthcare industry, today announced that it has acquired a majority stake in Lenis Group ("Lenis" or "the Company"), a fast-growing Slovenian-based full-service regional commercialization and distribution partner for niche and specialty Rx medicines in Central and Eastern Europe ("CEE").
  Dec 10, 2025
• ASH 2025: AbbVie and Genmab’s Epkinly sets new standard in second-line FL
  AbbVie and Genmab’s Epkinly triplet is poised to become a new standard of care for FL.
  Dec 10, 2025
• Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More
  Pre-Market Stock Futures: Futures are trading modestly lower as the big day has finally arrived: the Federal Reserve will wrap up its last meeting of 2025, and the odds still heavily favor a 25-basis-point rate hike. The worry hanging over traders is that many fear a “hawkish rate cut.” Where they do cut 25 basis ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More
  Dec 10, 2025
• Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada
  TORONTO, December 09, 2025--Biogen Canada Inc. today announced that Health Canada has issued a Notice of Compliance (NOC) for ZURZUVAE™ (zuranolone) for the treatment of moderate or severe postpartum depression (PPD) in adults following childbirth. ZURZUVAE is a once-daily, 14-day oral single course treatment for women with PPD. This first-of-its-kind treatment offers relief from depressive symptoms, with benefits seen in clinical studies as early as day 3, significant reduction of symptoms by t
  Dec 9, 2025
• 1 S&P 500 Stock to Keep an Eye On and 2 Facing Headwinds
  While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
  Dec 8, 2025
• Is Biogen Stock Outperforming the Dow?
  Biogen has notably outpaced the Dow in recent months and over the past year, and analysts remain moderately bullish on the stock’s prospects.
  Dec 8, 2025
• Oppenheimer & Co. Inc. Strengthens Equities and Biotech Research Teams with Addition of Kostas Biliouris, Ph.D.
  Oppenheimer & Co. Inc., a leading investment bank, wealth manager and subsidiary of Oppenheimer Holdings (NYSE: OPY), today announced that Kostas Biliouris has joined the firm as Managing Director on its Biotech Research Team. He will report to William (Bill) Bird, Director of Research, and be based in New York City.
  Dec 8, 2025
• “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
  TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that anti-Aβ protofibril* antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), has been included in the “Commercial Insurance Innovative Drug List” (Chinese: 商业健康保险创新药品目录), recently introduced by the National He
  Dec 8, 2025
• Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)?
  In late November and early December 2025, Biogen and its partners Eisai, Stoke Therapeutics and Dayra Therapeutics reported new clinical data and collaborations spanning Alzheimer’s disease, Dravet syndrome and oral macrocyclic peptide research, including positive updates on lecanemab’s subcutaneous formulation and zorevunersen’s long-term effects. The latest findings suggest Biogen is deepening its presence in high-need neurological conditions with therapies that aim not only to relieve...
  Dec 7, 2025
• Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue?
  Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 5, 2025
• Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
  —Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of life— —Propensity score weighted analysis comparing the effects of zorevunersen to natural history showed reductions in seizures and improvements in cognition and behavior with dose levels and timepoints similar to and c
  Dec 5, 2025
• Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
  BEDFORD, Mass. & CAMBRIDGE, Mass., December 05, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced data presentations that further support the potential of zorevunersen, an investigational antisense oligonucleotide, as a disease-modifying medicine for Dravet syndrome. These data were presented at the 2025 American Epilepsy Society (AES
  Dec 5, 2025
• Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report?
  Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 3, 2025
• Tech Is Getting Left Behind in the S&P 500’s Latest Rebound
  Eli Lilly & Co, Cardinal Health Inc. and Biogen Inc. are among the top 10 performers in the S&P 500 since Oct. 28, the last time the index closed at a record. In contrast, the S&P 500 Information Technology index is down 4.2% since then, with bigger losses coming from Magnificent Seven stocks like Nvidia Corp. and Microsoft Corp. The moves suggest that investor are still skittish about the artificial intelligence trade as concerns linger about valuations and whether all the heavy spending on computing power will pay off with profits.
  Dec 3, 2025
• Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
  Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer’s disease by up to 8.3 years in low-amyloid group who started treatment at an early stage New safety and efficacy data presented at scientific symposium on subcutaneous formulation for LEQEMBI initiation treatment, which is under regulatory review in the United States TOKYO and CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tok
  Dec 3, 2025
• Biogen (BIIB): Assessing Valuation After Recent Share Price Gains
  Biogen (BIIB) shares have been actively discussed lately, as some investors weigh the stock's longer-term track record against recent performance. Over the past month, Biogen stock has climbed by 15%, which is higher compared to its returns from earlier periods. See our latest analysis for Biogen. Momentum has picked up for Biogen lately, with a 15% one-month share price return and year-to-date gains of 18%, signaling renewed optimism after a tough few years. Still, its 1-year total...
  Dec 2, 2025
• Pre-filled Syringe Presentation of BYOOVIZ®, Samsung Bioepis' Biosimilar to Lucentis (Ranibizumab), Gains European Approval
  INCHEON, Korea, December 02, 2025--Samsung Bioepis' Byooviz PFS gains European approval.
  Dec 2, 2025
• New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
  Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the latest data confirming the pharmacological effect of lecanemab (generic name, U.S. brand name: LEQEMBI®), an anti-Aβ protofibril* antibody, on Aβ protofibrils (PF) in cerebrospinal fluid (CSF) was presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. The findin
  Dec 2, 2025
• Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
  New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet syndrome treated with zorevunersen support the potential for disease modificationCAMBRIDGE, Mass and BEDFORD, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today annou
  Dec 1, 2025
• Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
  BEDFORD, Mass. & CAMBRIDGE, Mass., December 01, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced data presentations from studies of zorevunersen at the 2025 American Epilepsy Society (AES) Annual Meeting, taking place December 5-9 in Atlanta, Georgia.
  Dec 1, 2025
• Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
  If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Nov. 27, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has filed a new drug application for
  Nov 28, 2025
• How Recent Developments Are Rewriting the Story for Biogen
  Biogen’s fair value estimate has seen a modest uptick, now set at $178.07 compared to the previous $176.72. This change reflects slightly improved analyst confidence, supported by optimism around policy headwinds and progress in the company’s drug pipeline. Stay tuned to discover how investors can monitor these evolving narratives as market sentiment shifts. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Biogen. What Wall...
  Nov 27, 2025
• Hedge Funds Pile Into Health Stocks Leading Market in Rotation
  The S&P 500 Health Care Index is up 10% through Tuesday, outperforming the other 10 sectors in the benchmark for US stocks. Eli Lilly & Co. has surged 29% to become the first health company with a $1 trillion valuation. Regeneron Pharmaceuticals Inc., Merck & Co. and Biogen Inc. are all up at least 18% since the end of October.
  Nov 26, 2025
• Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline
  BIIB's research deal with Dayra targets oral macrocyclic peptides to advance its immunology pipeline and expand next-generation therapies.
  Nov 25, 2025
• Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
  LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha
  Nov 25, 2025
• FDA Decision Opens Bigger Market for Novartis’s Blockbuster Gene Therapy
  Zolgensma is only approved for infants with spinal muscular atrophy. Older people will be able to use a new version of the treatment, called Itvisma.
  Nov 25, 2025
• Novo's $5 Billion Alzheimer's Dream Just Died--And Investors Are Cratering the Stock
  A long-shot Ozempic trial collapse sends Novo Nordisk to its lowest levels since 2021, reigniting market fears.
  Nov 24, 2025
• Sector Update: Health Care Stocks Advance in Afternoon Trading
  Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.5% and the Health Car
  Nov 24, 2025
• Biogen to gain from Novo Nordisk Alzheimer’s failure, says Jefferies
  Investing.com -- Biogen shares could benefit from Novo Nordisk’s Phase III Evoke/Evoke+ trials failure, according to analysts at Jefferies.
  Nov 24, 2025
• Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership
  TORONTO & CAMBRIDGE, Mass., November 24, 2025--Versant Ventures today announced the launch of Dayra Therapeutics, a startup focused on developing oral macrocyclic peptides for a range of serious diseases. The company has secured more than $70 million in committed funding, including a collaboration with Biogen Inc. that will provide $50 million in upfront capital, as well as an equity commitment from Versant.
  Nov 24, 2025
• Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
  Oral macrocyclic peptides have the potential to offer biologic-like efficacy and safety in a convenient oral formatCollaboration further advances Biogen’s immunology strategy by broadening its early-stage pipeline and incorporating an additional clinically validated modality into its expanding immunology capabilities CAMBRIDGE, Mass. and TORONTO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Dayra Therapeutics today announced a research collaboration to discover and develop or
  Nov 24, 2025
• Novo Dives After Weight-Loss Pill Fails In Alzheimer's Disease; Biogen Jumps
  Novo Nordisk stock toppled Monday after its weight-loss pill failed to significantly slow the progression of Alzheimer's disease in two big studies.
  Nov 24, 2025
• Novo Nordisk Stock Falls. Why Its Alzheimer’s Trial News Is Hitting Shares.
  The drugmaker says an oral version of Wegovy improved Alzheimer’s-related biomarkers, but didn’t delay the disease’s progression.
  Nov 24, 2025
• Biogen strikes deal with Versant-backed biotech to expand immune portfolio
  Newly launched Dayra Therapeutics has agreed to identify for Biogen "oral macrocycle candidates" that go after "high-priority immunological targets."
  Nov 24, 2025
• Does EMA Support for High Dose Nusinersen Redefine the Bull Case for Biogen (BIIB)?
  In November 2025, Biogen received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval of a high dose nusinersen regimen for 5q spinal muscular atrophy, with a final European Commission decision expected by January 2026. This regulatory progress not only has the potential to expand treatment options for SMA patients in Europe but also strengthens Biogen’s position within the neurological disease treatment market. We'll...
  Nov 22, 2025
• AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know
  A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to
  Nov 21, 2025
• AI Stocks Are Taking a Beating. What to Buy Instead.
  November has been NO-vember when it comes to tech stocks. Investors are shunning artificial-intelligence leaders and other momentum names. Investors seem to be embracing drug stocks, insurers, and medical equipment companies again.
  Nov 21, 2025
• Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference
  New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for additional long-term clinical benefits with continued treatment, and real-world experienceBiogen is committed to deepening scientific understanding of Alzheimer’s disease, including therapeutic delivery and disease progression CAMBRIDGE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at th
  Nov 20, 2025
• Healthcare’s Momentum Gathers Steam. 3 Stocks With Bullish Charts.
  FEATURE Healthcare stocks are recovering strongly as the year winds down. The is the best-performing of 11 major S&P sector funds over the past week, month, and three-month periods. The appeal of this group is its variety.
  Nov 19, 2025
• A Look at Biogen (BIIB) Valuation Following New Dravet Syndrome Study Results
  Biogen (BIIB) and Stoke Therapeutics just published final results from the two-year BUTTERFLY study. The data highlights that neurodevelopment in Dravet syndrome patients plateaus at around age two, despite currently available therapies. See our latest analysis for Biogen. Biogen’s share price has gained real momentum in recent weeks, climbing 15.2% in the past month and 18.6% over the last 90 days, after a prolonged period of lackluster returns. Despite a recent flurry of product news and...
  Nov 18, 2025
• Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion
  The Global Microscopic Polyangiitis (MPA) market is experiencing growth driven by the adoption of biologic therapies, which offer targeted mechanisms and improved relapse prevention. MPA, a rare ANCA-associated vasculitis, affects small blood vessels, posing risks to vital organs such as kidneys and lungs. Diagnosis requires ANCA testing and biopsies, with treatment involving corticosteroids, cyclophosphamide, and rituximab, alongside new therapies like avacopan. Despite challenges like high bio
  Nov 18, 2025
• Biogen acquires Alcyone to boost CNS drug delivery
  ThecaFlex DRx is an implantable device designed to improve treatment options for patients with neurological disorders.
  Nov 17, 2025
• High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
  Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12mg dose regimen1Final European Commission decision expected in January 2026SMA is a rare, genetic, neuromuscular disease that affects individuals of all ages2 CAMBRIDGE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the Committee for Medicinal Products for Human
  Nov 17, 2025
• Biogen Stock: Is Wall Street Bullish or Bearish?
  Despite Biogen's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.
  Nov 17, 2025
• Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
  – Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development – – Findings underscore the urgent need for new medicines that target the underlying genetic cause of Dravet syndrome to improve long-term outcomes – CAMBRIDGE, Mass. and BEDFORD, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Thera
  Nov 17, 2025
• Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
  BEDFORD, Mass., & CAMBRIDGE, Mass., November 17, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB) today announced the publication of final data from the BUTTERFLY study, a prospective, two-year natural history study in people with Dravet syndrome. Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) characterized by recurrent
  Nov 17, 2025
• Biogen Completes Acquisition of Alcyone Therapeutics
  CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery solutions, such as the ThecaFlex DRx™ drug delivery system. ThecaFlex DRx™ is an investigational implantable device designed to provide an alternative to repeat lumbar punctures in chronic intrathecal administration of medicines, which could ease both patient experience and access
  Nov 14, 2025
• “LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom
  TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the Medicines and Healthcare product
  Nov 13, 2025
• Antibody-Mediated Rejection Market Set to Expand Significantly During the Forecast Period (2025-2034) Amid Advances in Diagnostics and Targeted Therapies | DelveInsight
  DelveInsight's Antibody-mediated Rejection Market Insights report includes a comprehensive understanding of current treatment practices, antibody-mediated rejection emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
  Nov 11, 2025
• Should Biogen’s (BIIB) Surging New Drug Sales Reshape Investors’ Expectations for Future Growth?
  Biogen recently reported third quarter 2025 earnings results that surpassed expectations, with revenue rising to US$2.53 billion and net income increasing to US$466.5 million compared to a year ago, fueled by strong sales from newly launched therapies such as LEQEMBI, SKYCLARYS, and ZURZUVAE. This performance helped offset declines in Biogen's established multiple sclerosis franchise and prompted renewed analyst confidence in the company’s evolving drug portfolio. We'll explore how Biogen’s...
  Nov 8, 2025
• Biogen Shares Recover Slightly Amid Clinical Trial Partnerships — Is the Stock Trading Below Fair Value?
  Wondering if Biogen stock is priced for opportunity or risk? You are not alone. There is a lot more beneath the surface to consider when assessing its true value. Recently, Biogen’s share price has seen a modest climb, up 4.8% over the past week and 3.0% in the last month. However, it is still down 9.9% over the past year, pointing to both shifting expectations and evolving market sentiment. Several headlines have caught investor attention, including new clinical trial partnerships and...
  Nov 7, 2025
• Stifel lifts Biogen to Buy, sees potential Alzheimer’s narrative shift
  Investing.com -- Stifel upgraded Biogen (NASDAQ: BIIB) to Buy from Hold in a note Thursday, raising its price target to $202 from $144, saying the stock’s risk/reward profile is improving ahead of multiple clinical catalysts and a potential “narrative shift” in Alzheimer’s disease.
  Nov 6, 2025
• 5 Insightful Analyst Questions From Biogen’s Q3 Earnings Call
  Biogen’s third quarter results came in ahead of Wall Street’s revenue and profit expectations, driven by robust performance from recently launched products and continued strength in its multiple sclerosis portfolio. Management attributed much of the growth to LEQEMBI, SKYCLARYS, and ZURZUVAE, which together posted significant year-on-year gains. CEO Christopher Viehbacher highlighted that “launch products again in this quarter, and if I look at this year-to-date as well, more than have offset th
  Nov 6, 2025
• Caterpillar upgraded, Elf Beauty downgraded: Wall Street's top analyst calls
  Caterpillar upgraded, Elf Beauty downgraded: Wall Street's top analyst calls
  Nov 6, 2025
• Here Are Thursday’s Top Wall Street Analysts Research Calls: Amazon.com, Biogen, Caterpillar, e.l.f. Beauty, Southern Company and More
  Pre-Market Futures: The futures are trading modestly higher on Thursday after a big snap-back rally on Wednesday, as all the major indices staged a solid rebound following the Tuesday sell-off. While some of the buying was likely “Buy the Dip” investors doing what has come naturally for the last three years, another possible tailwind was ... Here Are Thursday’s Top Wall Street Analysts Research Calls: Amazon.com, Biogen, Caterpillar, e.l.f. Beauty, Southern Company and More
  Nov 6, 2025
• Braveheart secures $185M to advance challenger to Bristol Myers heart drug
  The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of similar treatments for hypertrophic cardiomyopathy.
  Nov 5, 2025
• Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
  Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights into the mechanism of action of felzartamab and advancing the understanding of its disease modifying potentialExhibitor Spotlight to discuss role of CD38 cells across a range of immune-mediated kidney diseasesFelzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of immune-mediated
  Nov 3, 2025
• BIIB Q3 Deep Dive: New Product Launches Offset Guidance Cut, R&D Pipeline Expands
  Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q3 CY2025, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was 23.9% above analysts’ consensus estimates.
  Oct 31, 2025
• Biogen (BIIB): One-Time $471M Loss Raises Fresh Doubts Over Rebounding Profit Narrative
  Biogen (BIIB) delivered a notable turnaround this year, posting EPS growth of 32.1% after five years of average annual declines of 20.5%. Net profit margins improved to 15.3% from last year’s 12%. Forecasts now call for earnings to grow at 7.3% per year, even as revenue is expected to decline at a 0.8% annual rate over the next three years. With shares trading at $149.61, well below the estimated fair value of $333.62 and a price-to-earnings ratio of 14.3x compared to the industry average of...
  Oct 31, 2025
• Biogen (BIIB) Valuation: Exploring the Discount as Investor Sentiment Shifts
  Biogen (BIIB) shares have shown some movement recently, and investors may be taking a closer look at what is driving performance. Over the past month, the stock has dipped around 3%. See our latest analysis for Biogen. While Biogen’s share price has dipped nearly 3% over the past month, the bigger picture shows momentum has faded, with a 90-day share price return of over 13% but a disappointing 1-year total shareholder return of -14%. That mix of short-term growth and long-term declines...
  Oct 31, 2025
• Biogen Inc (BIIB) Q3 2025 Earnings Call Highlights: Strong Product Launch Growth and Strategic ...
  Biogen Inc (BIIB) reports robust financial performance with significant growth in launch products and a focus on expanding its pipeline for future success.
  Oct 30, 2025
• Biogen's Growth Drivers Hit Third-Quarter Snags; Why This Isn't A 'Fundamental' Problem
  Two of Biogen's key growth drivers hit snags in the third-quarter. But Biogen stock yo-yoed and, most recently, edged down slightly.
  Oct 30, 2025

BIIB Reviews

• VolatilityCore

  Dec 30, 2025

  $BIIB This organization is at the forefront of neurological research, offering promising therapies that address critical health needs. Their pipeline of innovative treatments could significantly impact patient care in the years ahead.

  Buy

• TradeHex

  Dec 30, 2025

  $BIIB Known for its groundbreaking research and innovative therapies, the company remains at the forefront of the biotechnology field, promising exciting advancements.

  Buy

• MarketMarauder

  Dec 30, 2025

  $BIIB This biotech is more like buy-no-thank-you.

  Sell

• GainsOverBrains

  Dec 29, 2025

  $BIIB Playing the long game in health, they’re the real deal in biotech!

  Buy

• ShortKingston

  Dec 28, 2025

  $BIIB If this stock were a video game, it’d definitely be the one with all the cool power-ups for your health! Level up!

  Buy

• RiskWraith

  Dec 27, 2025

  $BIIB The pressure to deliver groundbreaking treatments is immense, and the market won't wait for anyone! If they stumble, investors could be in for a turbulent ride. Can they rise to the challenge?

  Sell

• DividendDemon

  Dec 27, 2025

  $BIIB This company’s breakthroughs are like a surprise party—totally unexpected and 100% worth celebrating! Just bring the confetti and cake.

  Buy

• TradeBlitz

  Dec 27, 2025

  $BIIB This stock is like a mad scientist in a lab coat—always cooking up something groundbreaking. It's got the brains and the brawn!

  Buy

• CryptoCobra

  Dec 27, 2025

  $BIIB Investing here is like betting on the geek squad winning the science fair. Smart money, but don't ask them to play sports!

  Buy

• TheMemeInvestor

  Dec 26, 2025

  $BIIB Solid ground but feelin’ a bit shaky lately, tread carefully!

  Sell

• VolatilityStrike

  Dec 26, 2025

  $BIIB With a strong portfolio of innovative therapies, this biotechnology leader continues to make strides in addressing complex diseases. Their focus on research and commitment to improving patient outcomes positions them well in the healthcare sector.

  Buy

• OptionRogue

  Dec 26, 2025

  $BIIB This company is making significant strides in the biotechnology sector, particularly with innovative therapies that could reshape treatment paradigms. Their focus on neurological disorders positions them well for future growth in a critical market segment.

  Buy

• TradeBlaze

  Dec 26, 2025

  $BIIB With a strong focus on biotechnology, this organization is dedicated to addressing serious medical conditions through innovative therapies. Their commitment to research positions them as a leader in the healthcare field.

  Buy

• DividendJunkie

  Dec 26, 2025

  $BIIB Trying to find growth in a sea of aging products.

  Sell

• StonkViking

  Dec 26, 2025

  $BIIB Playing the health game, gotta watch those charts closely.

  Sell

• StonkSamurai

  Dec 26, 2025

  $BIIB When it comes to brains and biotech, this one’s flexing hard!

  Buy

• AlphaRogue

  Dec 26, 2025

  $BIIB This company is like a magician—pulling rabbits out of hats and making health issues disappear like they were never even there!

  Buy

• ProfitGremlin

  Dec 26, 2025

  $BIIB Bringing breakthroughs, always got something cookin' in the lab!

  Buy

• StockSpecter

  Dec 24, 2025

  $BIIB Once a leader, now just limping along.

  Sell

• IndexPredator

  Dec 24, 2025

  $BIIB With the race for groundbreaking treatments ongoing, the pressure to deliver results is immense! How will this pharmaceutical giant navigate the tumultuous waters of drug discovery?

  Sell

• OptionRogue

  Dec 24, 2025

  $BIIB This biopharmaceutical company continues to push boundaries with its research and development in neurodegenerative diseases, showcasing a robust pipeline that could have a significant impact on patient outcomes.

  Buy

• FinTechNomad

  Dec 21, 2025

  $BIIB As research pipelines face scrutiny, the pressure to deliver results heightens. Patients and investors alike are waiting anxiously to see what unfolds.

  Sell

• ShortRaid

  Dec 21, 2025

  $BIIB This company operates in the biopharmaceutical sector, providing innovative solutions for neurological diseases. Its research-driven approach and strong pipeline reflect potential for significant growth.

  Buy

• TrendScript

  Dec 20, 2025

  $BIIB Recent advancements in neuroscience research have positioned this company at the forefront of developing groundbreaking therapies, making it a key player in improving patient care.

  Buy

• BullishVanguard

  Dec 20, 2025

  $BIIB The glory days are long gone; good luck catching up.

  Sell

• EquityEnigma

  Dec 18, 2025

  $BIIB With all the recent fluctuations, every update feels like a gut punch. It's a battlefield out there, one moment you're on top, and the next, you’re scrambling to keep up!

  Buy

• DividendVandal

  Dec 18, 2025

  $BIIB As a key player in the biotechnology field, this organization is known for its impactful contributions to medicine. Their focus on research and development continues to foster hope for groundbreaking discoveries.

  Buy

• ShortSurge

  Dec 17, 2025

  $BIIB This company is a key player in biopharmaceuticals, dedicated to advancing treatments for neurological diseases. Its robust pipeline and recent advancements indicate a bright future in addressing complex health challenges.

  Buy

• MarketRender

  Dec 17, 2025

  $BIIB With breakthroughs on the line, will they become the hero or the cautionary tale? The tension is palpable, and every announcement sends shockwaves!

  Buy

• RiskProtocol

  Dec 17, 2025

  $BIIB With the relentless pressure of competition and constant market fluctuations, this company stands at a critical juncture. The stakes are high, and every decision could send shockwaves through its future!

  Sell

• YOLOTrader69

  Dec 16, 2025

  $BIIB This player is staying in the mix, keep your ears open!

  Buy

• MarginMyth

  Dec 16, 2025

  $BIIB Once a giant, now just a shadow of past glories.

  Sell

• FOMOKing

  Dec 13, 2025

  $BIIB Bullish flow dominating options chain.

  Buy

• RiskAssassin

  Dec 13, 2025

  $BIIB Continuation to downside expected.

  Sell

• TheQuantEdge

  Dec 13, 2025

  $BIIB Failed support retest = bearish.

  Sell

• BullishSniper

  Dec 12, 2025

  $BIIB They’re basically the superheroes of the biotech world. If anyone can save the day, it’s this squad with their fancy lab coats and brainy breakthroughs!

  Buy

• AlgoAce

  Dec 12, 2025

  $BIIB They’re in the brain game, and let’s be real, we could all use a little help in that department—especially before exams!

  Buy

• YOLOTrader

  Dec 12, 2025

  $BIIB Sellers draining momentum.

  Sell

• TickerTrickster

  Dec 12, 2025

  $BIIB Strong supply zone overhead.

  Sell

• AlphaStriker

  Dec 12, 2025

  $BIIB High probability bearish breakdown.

  Sell

• FiscalRiot

  Dec 12, 2025

  $BIIB Trend weakening with heavy downside risk.

  Sell

• GainMachine

  Dec 12, 2025

  $BIIB Market participants showing confidence.

  Buy

• MarginMythic

  Dec 11, 2025

  $BIIB In the high-stakes world of pharmaceuticals, breakthroughs are expected, and delays can be disastrous. The clock is ticking for this firm to make significant advances or risk losing momentum in the market.

  Sell

• FiscalFury

  Dec 11, 2025

  $BIIB They say brains are sexy, and this stock's got the intellectual charm to sweep the research world off its feet—just don’t let it overthink the relationship.

  Buy

• ShortSurge

  Dec 11, 2025

  $BIIB The company is actively advancing critical therapies aimed at neurological disorders. As the healthcare landscape evolves, their focus on research and development positions them as a key player in improving patient outcomes.

  Buy

• MemeInvestor

  Dec 11, 2025

  $BIIB Impressive resilience against selling.

  Buy

• OptionOverlord

  Dec 11, 2025

  $BIIB High probability bearish breakdown.

  Sell

• DividendDegen

  Dec 11, 2025

  $BIIB Corrections are shallow — strong sign.

  Buy

• PortfolioPunk

  Dec 10, 2025

  $BIIB Medications that work better in theory than in reality.

  Sell

• ShortSavior

  Dec 10, 2025

  $BIIB Great if you love paying a premium for slow progress.

  Sell

• LiquidLegend

  Dec 9, 2025

  $BIIB This company is like that friend who always brings snacks to the party—just makes everything better and keeps you coming back for more!

  Buy

• RiskAssassin

  Dec 9, 2025

  $BIIB Massive potential for upside extension.

  Buy

• MarginDagger

  Dec 9, 2025

  $BIIB Chart structure screaming bullish continuation.

  Buy

• TickerTakedown

  Dec 9, 2025

  $BIIB Continuation to downside expected.

  Sell

• BearishBoi

  Dec 9, 2025

  $BIIB This stock is like a genius in class—everyone's secretly hoping it spills all the answers during the big test!

  Sell

• LiquidityLord

  Dec 9, 2025

  $BIIB As a prominent player in biotechnology, this company is advancing the frontiers of neuroscience research. Their ongoing pipeline of innovative therapies may provide significant breakthroughs in the treatment of neurological conditions.

  Buy

• TradeBlitz

  Dec 8, 2025

  $BIIB This stock is like a high school science project that actually worked – who knew brains could be so profitable?

  Buy

• EarningsSync

  Dec 8, 2025

  $BIIB With the spotlight on biotech, this company must navigate choppy waters and deliver results fast. Will they rise to the occasion or sink under pressure?

  Buy

• StonkDestroyer

  Dec 7, 2025

  $BIIB Hope you enjoy watching your money disappear.

  Sell

• TradePredator

  Dec 7, 2025

  $BIIB This stock’s glory days are long gone, my friend.

  Sell

• BullRunBoss

  Dec 6, 2025

  $BIIB This one's like that brainy friend who always knows the answers—super smart and kinda hard to keep up with!

  Buy

• RiskReaper

  Dec 6, 2025

  $BIIB As a leader in biopharmaceuticals, this organization consistently pushes the boundaries of science to deliver breakthrough therapies. Their ongoing research initiatives could yield significant advancements in treatment options.

  Buy

• QuantSpecter

  Dec 4, 2025

  $BIIB The pressure is mounting as this biotech titan faces fierce competition. Can it innovate fast enough to keep its edge? The stakes have never been higher!

  Sell

• RiskAssassin

  Dec 4, 2025

  $BIIB The developments in this sector are thrilling yet nerve-wracking. Can they maintain momentum, or is the competition breathing down their necks?

  Buy

• TraderFury

  Dec 4, 2025

  $BIIB Health concerns and market volatility are casting shadows over this biotech firm. The stakes have never been higher—can they innovate fast enough to make a real impact?

  Buy

• TheStockKnight

  Dec 4, 2025

  $BIIB Big breakdown likely incoming.

  Sell

• ShortRaid

  Dec 4, 2025

  $BIIB Bullish reversal well underway.

  Buy

• AlphaDecoder

  Dec 3, 2025

  $BIIB This established player in the biotechnology sector continues to showcase its research capabilities, making significant contributions aimed at addressing some of the most pressing health challenges.

  Sell

• ShortCircuit

  Dec 3, 2025

  $BIIB Aging like fine wine, or just gone sour?

  Sell

• RiskRanger

  Dec 3, 2025

  $BIIB They’re like the wizards of the biotech world, brewing potions to keep our brains sharp. Just no potion spills, please!

  Buy

• PortfolioPunk

  Dec 2, 2025

  $BIIB You’ve lost your edge; time to step aside.

  Sell

• YieldHunter

  Dec 2, 2025

  $BIIB This company is at the forefront of innovative treatments, making significant strides in the biotech sector. With a strong pipeline and promising research advancements, it remains a noteworthy player in the industry.

  Buy

• StockSpecter

  Dec 1, 2025

  $BIIB Another overpriced biotech with more hype than substance.

  Sell

• FinTechFrost

  Dec 1, 2025

  $BIIB This company is like that really smart kid in school – always raising the bar and making the rest of us look bad!

  Buy

• BagholderElite

  Dec 1, 2025

  $BIIB This biopharma champ’s always coming with the breakthroughs, keep an eye!

  Buy

• WallStreetVandal

  Nov 30, 2025

  $BIIB What a bumpy ride; maybe try rollercoasters instead.

  Sell

• PortfolioGremlin

  Nov 29, 2025

  $BIIB Kicking it strong in the bio scene, making waves like a boss!

  Buy

• BagholderPrime

  Nov 29, 2025

  $BIIB This stock is like a brainy scientist at a wild party—full of potential but sometimes a bit slow to get the groove on!

  Buy

• MarginMeme

  Nov 29, 2025

  $BIIB Biotech’s blowing up and they’re in the thick of it, keep vibes high!

  Buy

• RiskWraith

  Nov 29, 2025

  $BIIB The biotech field is fraught with opportunity and despair! Will this company revolutionize healthcare or face setbacks at every turn? What a tightrope walk!

  Buy

• BearEater

  Nov 28, 2025

  $BIIB Known for its impactful contributions to the biotechnology field, the company continues to innovate, thereby improving its competitive edge in the healthcare market.

  Buy

• TradeBlitz

  Nov 27, 2025

  $BIIB This company is like that friend who always has a bizarre fact ready. You might just learn something funky about your brain!

  Sell

• TrendHunter

  Nov 27, 2025

  $BIIB Once a giant, now just limping along—yikes.

  Sell

• TickerTrickster

  Nov 27, 2025

  $BIIB Innovations flow like a river here, stay woke on this one!

  Buy

• TraderFury

  Nov 25, 2025

  $BIIB In the high-stakes game of biotech, this company is facing mounting pressure from competitors and regulatory hurdles. Will their innovations shine through, or stumble in the shadows?

  Sell

• MoonBagz

  Nov 25, 2025

  $BIIB Facing some heat, better watch your back!

  Sell

• ShortSniper

  Nov 24, 2025

  $BIIB Legacy stock trying too hard to stay relevant.

  Sell

• DividendJunkie

  Nov 23, 2025

  $BIIB Still chasing innovation like it's a fleeting dream.

  Sell

• CashClown

  Nov 23, 2025

  $BIIB Been around the block, but is it time to shine again?

  Sell

• BullishBerserker

  Nov 23, 2025

  $BIIB With their history of breakthroughs, the anticipation is electric. But can they navigate the storm of competition and regulatory scrutiny? The pressure is mounting as we hold our breath!

  Buy

• FiscalBinary

  Nov 22, 2025

  $BIIB With breakthroughs and setbacks in biotech happening at breakneck speed, it's an intense race to stay ahead, and the stakes couldn't be higher for investors.

  Buy

• CashOverload

  Nov 22, 2025

  $BIIB Desperate for a miracle? This one's all out of magic.

  Sell

• MarketSavage

  Nov 22, 2025

  $BIIB Sure, they have a legacy, but does anyone still care?

  Sell

• PortfolioPunk

  Nov 21, 2025

  $BIIB Struggling to stay relevant while the competition zooms by.

  Sell

• DividendHunter

  Nov 21, 2025

  $BIIB Stuck in a lab of regrets—good luck escaping.

  Sell

• VolatilityStrike

  Nov 21, 2025

  $BIIB As a leader in neurological treatments, this company is deeply committed to tackling complex health challenges. Its robust pipeline of therapies offers hope for many, with the potential for substantial advancements in patient care.

  Buy

• VolatileViking

  Nov 19, 2025

  $BIIB This stock is like a brainy scientist at a party—everyone's curious and hoping it brings some genius ideas!

  Buy

• DividendGhost

  Nov 19, 2025

  $BIIB The pharmaceutical landscape is a battlefield, and with every announcement, investors are left on edge. Can this company deliver breakthroughs, or are they just another name lost in the noise?

  Sell

• MoneyMage

  Nov 19, 2025

  $BIIB Once a giant, now just chasing its own tail.

  Sell

• RiskAssassin

  Nov 18, 2025

  $BIIB With patent expirations looming, tensions are rising. Investors are on edge, waiting to see if innovation can fend off the impending competition.

  Sell

• YOLOTrader

  Nov 18, 2025

  $BIIB Like that one friend who always brings snacks to the party—everyone loves them, but sometimes they hog the good stuff!

  Sell

• LiquidLegend

  Nov 18, 2025

  $BIIB This one’s like the nerd in class—you know they’ve got the smarts, just hoping they don’t trip over their own shoelaces during the science fair!

  Sell

• FiscalEngine

  Nov 17, 2025

  $BIIB This organization continues to lead in the biopharmaceutical arena, particularly in treating neurological conditions. With a robust pipeline of innovative therapies, it is well-placed to make a significant impact on patient outcomes.

  Buy

• RocketDividend

  Nov 17, 2025

  $BIIB Battlin’ in biopharma, got potential but watch the storms.

  Sell

• MissionOverlord

  Nov 17, 2025

  $BIIB They’re in the game with some serious brainpower, keep an eye out!

  Buy

• DividendGhost

  Nov 16, 2025

  $BIIB Facing intense scrutiny and breakthroughs in the biotech arena, this corporation is walking a tightrope. Every misstep could lead to disastrous consequences in a field where timing is everything.

  Sell

• Stonks4Days

  Nov 15, 2025

  $BIIB Big brains and solid vibes here, definitely one to keep on the radar.

  Buy

• TickerPhantom

  Nov 14, 2025

  $BIIB This company is at the forefront of biotechnology, focusing on innovative therapies that target neurological diseases. With a strong pipeline and commitment to research, it has the potential to significantly impact the healthcare landscape.

  Buy

• BearWithMe

  Nov 14, 2025

  $BIIB In the lab cookin' up something big; hold tight for the reveal!

  Buy

• PriceBreaker

  Nov 14, 2025

  $BIIB As a key player in biotechnology, this company is known for its impactful research and strong portfolio of therapies aimed at critical health issues. Their commitment to innovation could pave the way for significant advancements.

  Buy

• YOLOTrader

  Nov 14, 2025

  $BIIB This company is like the brainiac in class – always coming up with genius ideas to help everyone else!

  Buy

• BullishBerserker

  Nov 13, 2025

  $BIIB In the biopharma world, every breakthrough can turn into a nightmare of competition. It’s a high-stakes game that keeps you on edge!

  Sell

• AlphaStriker

  Nov 12, 2025

  $BIIB Another overpriced biotech waiting for a miracle that won't come.

  Sell

• TradeProtocol

  Nov 10, 2025

  $BIIB Feeling like a genius? This stock might just give your brain the boost it needs, minus the side effects!

  Buy

• TradeBlitz

  Nov 10, 2025

  $BIIB If brains were dollars, this company would be a billionaire—just hope they don’t lose their marbles in the process!

  Sell

• GainsJester

  Nov 9, 2025

  $BIIB Brains in biotech, they're about to school the competition!

  Buy

• MarketReaper

  Nov 9, 2025

  $BIIB This company's got more brains than a zombie movie but way less biting action!

  Buy

• ProfitShade

  Nov 9, 2025

  $BIIB Innovating like a boss, they got the streets talking about them.

  Buy

• DividendDegen

  Nov 8, 2025

  $BIIB In the science game, making waves, but is it enough? Keep it in mind!

  Sell

• TheTradingVerse

  Nov 7, 2025

  $BIIB This organization remains at the forefront of biopharmaceutical advancements, consistently pushing boundaries in neurological research. Its strong pipeline of therapies shows promise, providing hope for patients and creating potential value for stakeholders. The recent developments hint at a resilient future in a competitive landscape, capturing attention for its innovative potential.

  Buy

• TickerFlux

  Nov 2, 2025

  $BIIB Technicals said no, emotions said yes - as usual. Trend line straighter than my diet plan.

  Buy

• QuantSpecter

  Oct 31, 2025

  $BIIB should to action green to investors express allergic train pain price CEO is

  Sell

• OptionShadow

  Oct 30, 2025

  $BIIB tight macro steady tight no breakout theta today soon noise clean keeping go tape eyes heater printing range hands tape range patience tight earnings soon-ish keeping

  Buy

• YOLOTrader69

  Oct 28, 2025

  $BIIB than like GPA faster dumpster my fire falling lately

  Sell

• MarginMeme

  Oct 20, 2025

  $BIIB clown this show fire absolute my hurts

  Sell

• RiskDriver

  Oct 15, 2025

  $BIIB in operas better I've allergic candles cave seen to price recoveries

  Sell

• PnLPhantom

  Oct 12, 2025

  $BIIB Vibes are bullish and my coffee agrees. Momentum so steady it could teach.

  Sell

• TheGainReaper

  Oct 11, 2025

  $BIIB buzzing soon it steady risk on nasty earnings printing hurts hard hands theta rocket trigger today flows keeping fast bounce eyes energy feels spike

  Buy

• PnLPhantom

  Sep 16, 2025

  $BIIB soon bull staying staying whispers king imo risk ath gap soon theta no heavy

  Buy

• RiskAssassin

  Sep 8, 2025

  $BIIB alpha sentiment level-to-level range heater clean crushing charts keeping tight clear queued tax no feels eyes smart nimble nimble money wild maybe soon-ish smart tbh clean alpha tbh nasty here

  Buy

• OptionCipher

  Sep 7, 2025

  $BIIB Energy in this move is contagious - someone call CNBC.

  Sell

• DividendHunter

  Aug 27, 2025

  $BIIB That breakout had better timing than my morning coffee. If.

  Sell

• MoonBagz

  Aug 26, 2025

  $BIIB heavy trap sauce rip eyes here noise imo mess talking diamond buzzing feels macro buzzing vol soon clear noise level-to-level humming today volume

  Sell

• AlphaHawk

  Aug 22, 2025

  $BIIB train cave bear pain residence confirmed express

  Sell

• MarketGlitch

  Aug 22, 2025

  $BIIB loud loud nimble sentiment diamond flows queued tight soon strong maybe mode today volume bounce imo levels hurts bounce heat smooth nasty steady no keeping levels diamond tbh fast

  Buy

• PortfolioPunk

  Aug 21, 2025

  $BIIB nasty today tax sentiment humming tax whispers clear maybe bagholder talking nasty tax on broken level-to-level maybe buzzing humming fast heating heating money nasty mode clear liquidity sentiment flows

  Sell

• VolatileViking

  Aug 13, 2025

  $BIIB tape trend tbh supply today theta energy wick theta ouch look

  Sell

• MemeInvestor

  Aug 1, 2025

  $BIIB uptrend rocket and heat move eyes talking mode watching gap

  Buy

• TrendScript

  Jan 14, 2025

  $BIIB fading today bleeding rough lows here humming vol liquidity wick noise

  Sell

• QuantumBroker

  Dec 24, 2024

  $BIIB wall choppy nasty smart vibes talking sentiment dead bleeding theta hard

  Sell

• ProfitLancer

  Sep 3, 2024

  $BIIB tape tight earnings beastly whoa it frankly tape wild on soon-ish soon diamond watching levels king hedges smart bull heating

  Buy

• PortfolioPunk

  Sep 2, 2024

  $BIIB tape and flows passed pumping beastly clean whispers oversold tbh

  Buy

• BearishBoi

  Aug 6, 2024

  $BIIB wall it whispers bagholder heavy lows ugly rip frankly charts loud mode

  Sell

• BullishShade

  Jul 12, 2024

  $BIIB check hedges diamond dripping tape noise here flows heavy range talking clean volume diamond soon-ish today levels run smart today

  Buy

• TrendScript

  Jul 11, 2024

  $BIIB dive rough queued dumping noise talking soon talking humming mess bleeding mess tape weak soon-ish

  Sell

• GainsOverBrains

  Jun 9, 2024

  $BIIB maybe today nimble soon keeping macro dripping steady grind run macro hedges bull run imo it flows heavy soon tape

  Buy

• FiscalFury

  May 24, 2024

  $BIIB nimble fire beastly alpha vibes momentum queued king bounce now levels

  Buy

• CapitalCarnage

  Apr 16, 2024

  $BIIB cliff dumping weak today candle charts clean buzzing weak tax

  Sell

• FinTechNomad

  Apr 5, 2024

  $BIIB bagholder now bagholder ouch nasty clean theta headfake ouch charts feels

  Sell

• ChartPhantom

  Feb 26, 2024

  $BIIB staying diamond move imo loud risk eyes theta steady soon maybe rocket soon-ish heat mode watching gains wild vol

  Buy

• StonkKnight

  Feb 2, 2024

  $BIIB smart humming talking ath heater trend gains sentiment uptrend nasty imo trend vibes

  Buy

• TradeRebel

  Jan 18, 2024

  $BIIB on patience smart no strong whoa trigger level-to-level bounce sentiment vol heater keeping tape keeping pumping buzzing

  Buy